menu
    • menu
    [{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"MET","graph1":"Oncology","graph2":"Undisclosed","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Foundation Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Mobocertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foundation Medicine \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Foundation Medicine \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Approved","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Foundation Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"HGF receptor","graph1":"Oncology","graph2":"Approved","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Foundation Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Aadi Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Nab-sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Foundation Medicine \/ Foundation Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Foundation Medicine \/ Foundation Medicine"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Arvinas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Bavdegalutamide","moa":"PROTAC protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foundation Medicine \/ Foundation Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Foundation Medicine \/ Foundation Medicine"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Selinexor","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foundation Medicine \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Foundation Medicine \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"BI 907828","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Boehringer Ingelheim","highestDevelopmentStatusID":"8","companyTruncated":"Foundation Medicine \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Foundation Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foundation Medicine \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Foundation Medicine \/ Pierre Fabre"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"AnHeart Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Foundation Medicine \/ Foundation Medicine"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Foundation Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Repare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Lunresertib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Repare Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Foundation Medicine \/ Repare Therapeutics"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"PMV Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Rezatapopt","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Foundation Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Foundation Medicine \/ Foundation Medicine"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Qu Biologics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"QBECO SSI","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Foundation Medicine \/ Foundation Medicine"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Janssen Biotech","highestDevelopmentStatusID":"14","companyTruncated":"Foundation Medicine \/ Janssen Biotech"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Merus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Zenocutuzumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Foundation Medicine","highestDevelopmentStatusID":"14","companyTruncated":"Foundation Medicine \/ Foundation Medicine"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Inavolisib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Foundation Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Olaparib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Foundation Medicine","highestDevelopmentStatusID":"14","companyTruncated":"Foundation Medicine \/ Foundation Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals by Foundation Medicine

    Menu

    Foundation Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves FoundationOne®Liquid CDx As Diagnostic For Itovebi™ in Breast Cancer

                            Details : FoundationOne®Liquid CDx to be used as a companion diagnostic for Itovebi (inavolisib) for adults with endocrine-resistant, PIK3CA-mutated HR+/HER2-breast Cancer.

                            Brand Name : Itovebi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 11, 2024

                            Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olaparib,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves FoundationOne®CDx As Companion Diagnostic for Prostate Cancer

                            Details : Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone indicated for the treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer.

                            Brand Name : Lynparza

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 03, 2024

                            Lead Product(s) : Olaparib,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zenocutuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Merus

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Foundation Medicine Collaborates with Merus to Advance NRG1 Fusion Tumor Treatment

                            Details : The collaboration aims to develop Foundation Medicine’s RNA platform as a companion diagnostic for Merus’s bispecific antibody MCLA-128 (zenocutuzumab) to treat neuregulin 1 fusion cancer.

                            Brand Name : MCLA-128

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 28, 2024

                            Lead Product(s) : Zenocutuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Merus

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : JANSSEN BIOTECH

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves FoundationOne®Liquid CDx as Companion Diagnostic for AKEEGA®

                            Details : Akeega (niraparib, abiraterone acetate) is a tablet works by inhibiting approved for BRCA-mutated mCRPC in adults. The FDA has approved FoundationOne Liquid CDx as its companion diagnostic.

                            Brand Name : Akeega

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 01, 2024

                            Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : JANSSEN BIOTECH

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lunresertib,Camonsertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Repare Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Foundation Medicine Partners with Repare for Genomic Profiling and Companion Diagnostic

                            Details : The collaboration aims to support Repare’s ongoing clinical development of RP-6306 (lunresertib) oral small molecule inhibitor of PKMYT1 alone or with camonsertib for the treatment of neoplasms.

                            Brand Name : RP-6306

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 12, 2024

                            Lead Product(s) : Lunresertib,Camonsertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Repare Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QBECO SSI

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Qu Biologics Inc

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Qu Biologics And Foundation Medicine Partner For Colorectal Cancer Care

                            Details : The partnership aims to impact the care of patients with late-stage colorectal cancer undergoing surgery in a Phase II trial assessing QBECO SSI in reducing post-operative immune suppression.

                            Brand Name : QBECO SSI

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 06, 2024

                            Lead Product(s) : QBECO SSI

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Qu Biologics Inc

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rezatapopt,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : PMV Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Foundation Medicine and PMV Pharma Collaborate on Diagnostic for Rezatapopt

                            Details : The partnership aims to develop Foundation Medicine’s FoundationOne®CDx, as a companion diagnostic for PMV’s PC14586 (rezatapopt), a first-in-class therapy for solid tumors with TP53 Y220C mutation.

                            Brand Name : PC14586

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 29, 2024

                            Lead Product(s) : Rezatapopt,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : PMV Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taletrectinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : AnHeart Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AnHeart Therapeutics and Foundation Medicine Announce Collaboration to Develop Tissue-Based and Liquid-Based C...

                            Details : The collaboration aims for the development and regulatory approval of Foundation Medicine’s FoundationOne®CDx and FoundationOne®Liquid CDx, as companion diagnostics for AnHeart’s investigational next-generation ROS1 inhibitor, taletrectinib, in the...

                            Brand Name : AB-106

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 14, 2023

                            Lead Product(s) : Taletrectinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : AnHeart Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capivasertib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for AstraZeneca’s Truqap™ (capivasertib) in...

                            Details : Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.

                            Brand Name : Truqap

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 20, 2023

                            Lead Product(s) : Capivasertib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Pierre Fabre

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Foundation Medicine Announces Collaboration with Pierre Fabre Laboratories to Develop Companion Diagnostics in...

                            Details : The companies will work to seek the regulatory approval for Foundation Medicine assays which detect mutations including BRAFV600E to identify patients for potential treatment with Pierre’s BRAF/MEK inhibitor, BRAFTOVI (encorafenib) and MEKTOVI (binimet...

                            Brand Name : Braftovi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 15, 2023

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Pierre Fabre

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth